Brain-computer-interface rehabilitation and neural interfaces

1. Introduction

Version followed: two separate things are described here. (1) Non-invasive BCI rehabilitation for chronic stroke, as the FDA's April 2021 De Novo authorisation of the Neurolutions IpsiHand Upper Extremity Rehabilitation System describes it, and as the brain-actuated functional electrical stimulation (BCI-FES) trial by Biasiucci, Millán and colleagues (Nature Communications, 2018) describes it. (2) Implanted assistive neural interfaces that are still research devices: BrainGate2, the Synchron Stentrode (COMMAND study) and Neuralink (PRIME study). Regulatory status was checked against the sources listed as of October 2026; the newest source dates are given in each entry. Status after those dates is [uncertain: not verified].

What it is. A brain-computer interface (BCI) records brain activity linked to the intention to move. It decodes that activity and uses it to drive something outside the body: a hand exoskeleton, muscle stimulation, a computer cursor or a communication interface. The two uses work differently.

Rehabilitation BCIs aim at recovery. When the person tries to move a weak hand, the system detects the attempt and makes the hand move at that same moment. The idea is that repeatedly closing this loop between intention and movement helps rebuild motor pathways. Biasiucci and colleagues attribute the lasting gains to the stimulation being contingent on the patient's own brain activity. Their control group received the same stimulation at random times and recovered less. [source: Biasiucci et al. 2018 via IDEAS/RePEc; EPFL news 2018]
Assistive implanted BCIs aim at replacing a function, not restoring it. People with severe paralysis (tetraplegia, ALS, brainstem stroke) use decoded signals to control a computer, communicate or operate assistive devices. [source: BrainGate clinical trials page; MassDevice 2024]

Scope for the psychotherapist. BCI rehabilitation is prescribed and delivered within rehabilitation medicine. The treating team is typically a physician (physiatry or neurology) together with occupational therapists and physiotherapists. [synthesis] Implanted BCIs are delivered by neurosurgical and research teams under investigational protocols. The psychotherapist does not operate, fit or adjust any of these systems. This guide is written for a therapist working alongside those teams. The therapist's work covers decision support, expectations, identity and agency, family and caregiver strain, data and privacy concerns, the end of a trial or of company support, and liaison with the team. No device settings or protocol parameters are given here.

Regulatory snapshot (as sources state, checked October 2026)

Device	Type	Status	Indication / population	Source date
IpsiHand (Neurolutions)	Non-invasive EEG headset, tablet, powered hand brace	FDA De Novo marketing authorisation, Breakthrough Device; prescription only	Adults 18 and older undergoing stroke rehabilitation; muscle re-education and maintaining or increasing upper-extremity range of motion	FDA press release, 23 Apr 2021
BrainGate2 Neural Interface System	Implanted intracortical	Investigational; labelled "limited by federal law to investigational use"; pilot feasibility study NCT00912041	Tetraplegia from cervical spinal cord injury, brainstem stroke, muscular dystrophy, ALS or other motor neuron disease	BrainGate site [date of page not shown; uncertain]
Stentrode (Synchron)	Endovascular, placed via the jugular vein into a venous sinus beside motor cortex	FDA investigational device exemption (IDE) feasibility study (COMMAND, 6 patients); pivotal trial under discussion with FDA	Severe paralysis	MassDevice and Medical Design & Outsourcing, 30 Sep 2024
Neuralink implant	Implanted	FDA IDE May 2023 (PRIME study); FDA Breakthrough Device designation for severe speech impairment, May 2025; premarket, not authorised for marketing	Paralysis (PRIME); speech impairment designation covers ALS, stroke, SCI, cerebral palsy, MS and other conditions, per the company	Medical Device Network, 2 May 2025

Numbers of Neuralink and Synchron participants and any pivotal-trial or marketing decisions after these dates are [uncertain: not verified]. Status in the EU (CE marking), UK (MHRA/UKCA) and other jurisdictions is [uncertain: not verified] for all four devices.

2. Framework

This is a device-based treatment delivered by a rehabilitation or research team, not a psychotherapy with its own phases. The phases below are the psychotherapist's frame around the medical pathway. [synthesis, built on the device descriptions cited]

Phase A: Considering a BCI (before referral or enrolment). Goal: an informed, unpressured decision with realistic expectations. Format: 1 to 4 sessions, individual or with family, alongside the team's own consent process. Move on when the client can describe in their own words what the device does and does not do. They should also be able to say what taking part involves and what happens if it fails or ends. For IpsiHand, the FDA describes a prescription device used within rehabilitation. Its pivotal evidence was an unblinded 40-patient study over 12 weeks. The company announcement describes home or clinic use about five days a week. [source: FDA 2021; WashU 2021] For BrainGate, the study page describes brain surgery, a 13-month commitment and living within three hours' drive of a study site. [source: BrainGate]

Phase B: Starting and early use. Goal: support engagement, frustration tolerance and early meaning-making. Format: sessions spaced to match the rehabilitation schedule. Move on when the client has a workable routine and a way to report problems to the team.

Phase C: Ongoing use and integration. Goal: integrate changes in function, the sense of agency and identity. Also attend to relationships and caregiver load, and keep monitoring mood and fatigue. Format: regular sessions, with liaison with the team at agreed points.

Phase D: Ending, plateau or loss of the device. Goal: prepare for the end of a rehabilitation course, a plateau, explantation, the end of a trial or a company withdrawing support. Format: planned sessions before the known end date, then follow-up. Documented cases show this phase can be traumatic. One participant in a seizure-warning implant trial had her device removed against her wishes after the company (NeuroVista) ran out of money in 2013. [source: MIT Technology Review 2023] Recipients of Second Sight's Argus II retinal implant were left without repairs or medical information when the company wound down in 2020. [source: IEEE Spectrum 2022]

Session counts above are [synthesis]; no source sets a psychotherapy dose for BCI care.

3. Guiding principles

Stay in your lane on the device. Never comment on settings, fit or how often to use it. Route all technical, medical and adherence questions to the treating team. [source: device is prescription-only per FDA 2021; synthesis]
Know the regulatory status and date it. Cleared or authorised is not the same as investigational. Name which applies and when you last checked. Example: IpsiHand is FDA-authorised for adults 18 and older in stroke rehabilitation, while BrainGate, Stentrode and Neuralink are research devices. [source: FDA 2021; BrainGate; MassDevice 2024; Medical Device Network 2025]
Hope is a resource and a risk. Support hope without inflating it. The Argus II investigator quoted by IEEE Spectrum said devices had been sold to patients relying on hope rather than proven performance. [source: IEEE Spectrum 2022]
Consent is a process, not a signature. Revisit understanding, values and freedom from pressure (family, clinicians, media) throughout. [synthesis]
Agency and identity are clinical material. People can come to experience a device as part of themselves, and losing it can feel like losing part of the self. [source: MIT Technology Review 2023, reporting Gilbert's interviews]
Neural data is sensitive data. Help clients ask who holds their brain data and under what law. Chile amended its constitution in October 2021 to protect brain activity. Colorado added neural data to its privacy act as sensitive data requiring opt-in consent (law on 17 April 2024), as the ABA source states. [source: ABA article]
Plan for the end from the start. Ask the team about post-trial support, explantation, MRI implications and what happens if the manufacturer fails. [source: IEEE Spectrum 2022; MIT Technology Review 2023]
Work as part of the team. With consent, share what is relevant (mood, fatigue, distress, safety) with the rehabilitation or research team. Clarify roles. [synthesis]
Include the family system. Caregivers often carry transport, set-up and emotional load, and they shape decisions. [synthesis]
Screen for post-stroke and disability-related mental health problems (depression, anxiety, adjustment, suicidality) with standard tools and refer as needed. [synthesis]

4. Intervention inventory

Part A gives a factual description of how the devices are delivered, at a descriptive level only. Part B gives the psychotherapist's own interventions.

Part A: How the treatments are delivered (descriptive)

A1. Non-invasive BCI stroke rehabilitation: IpsiHand (FDA-authorised)

Purpose: The FDA describes it as supporting muscle re-education and maintaining or increasing range of motion in the hand, wrist and arm. It is for adults 18 and older undergoing stroke rehabilitation, and it aims to improve grasping. [source: FDA press release 2021] The developers describe the target group as chronic stroke survivors. They describe it as using signals from the uninjured (same-side, ipsilateral) hemisphere. [source: WashU 2021; MedTech Dive 2021]
How it is delivered (as described): Non-invasive EEG electrodes in a wireless headset record brain activity. A tablet analyses the intended movement and signals a wireless powered brace worn over the hand, wrist and forearm, which opens and closes the hand. It is prescription only and may be used as part of rehabilitation therapy, at home or in clinic. [source: FDA 2021; MedTech Dive 2021; WashU 2021] The usage schedule and settings are set by the prescribing team. They are not given here.
Who should not use it (per FDA): People with severe spasticity or rigid wrist or finger contractures that prevent proper fitting of the brace. Also people with skull defects from craniotomy or craniectomy. [source: FDA 2021]
Reported adverse events (per FDA): Minor fatigue, discomfort and temporary skin redness. [source: FDA 2021]
Evidence basis named by FDA: An unblinded study of 40 patients over 12 weeks. All participants showed improved motor function. [source: FDA 2021] The FDA created a new device classification, so later devices of the same type may use the 510(k) route. [source: FDA 2021]
Therapist's use of this information: Psychoeducation and recognising when to refer back to the prescriber. Never troubleshoot the device.
Example language (illustrative): "From what the FDA published, this is a prescription device used as part of rehab. Your rehab team decides whether it fits you and how you use it. What I can help with is how you're finding it and what you hope it changes."
Watch for: Fatigue, discomfort or skin redness. Problems with fit because of spasticity. Discouragement if gains are slow. Pass physical complaints to the treating team.

A2. BCI-coupled functional electrical stimulation (research approach)

Purpose: Arm motor recovery in chronic stroke through stimulation that is contingent on brain activity. [source: Biasiucci et al. 2018]
How it is delivered (as described): EEG detects activity in the stroke-affected hemisphere when the patient attempts to reach. Each detection immediately triggers electrical stimulation of the wrist and finger muscles. In the trial, a control group received stimulation at random times. 27 patients took part, aged 36 to 76, with moderate to severe arm paralysis from a stroke at least ten months earlier. Recovery was greater with BCI-FES and lasted 6 to 12 months after therapy. [source: EPFL news 2018; Biasiucci et al. 2018] Stimulation parameters are not given here. Whether any BCI-FES system is commercially cleared is [uncertain: not verified].
Therapist's use: Explain the principle ("your attempt triggers the movement") so the client understands why effortful attempts matter. Do not coach technique; that belongs to the treating team. [synthesis]
Example language (illustrative): "The researchers think it helps because the stimulation comes at the exact moment your brain tries. So the trying itself is part of the treatment, even when the hand doesn't move much yet."
Watch for: Mental fatigue and frustration when attempts "don't register". Self-blame. Any wish to try home-made stimulation. DIY brain or muscle stimulation outside a supervised programme should be discouraged and raised with the team. [synthesis]

A3. Implanted assistive BCIs (investigational)

Purpose / when [synthesis]: use these dated facts when a client is considering, enrolled in or leaving an implanted-BCI study, so that research participation is not mistaken for an available treatment.

BrainGate2: A pilot feasibility study of an intracortical neural interface (NCT00912041). It aims to gather preliminary safety information and show that people with tetraplegia can control a computer cursor, assistive devices and communication software by imagining hand movement. It involves surgery and a 13-month commitment. Sites are in the US (Massachusetts General Hospital, VA Providence, Stanford, Emory, UC Davis, Baylor). The device is labelled "limited by federal law to investigational use". The page does not describe what happens after the study. [source: BrainGate clinical trials page]
Synchron Stentrode (COMMAND): Delivered by catheter through the jugular vein into the superior sagittal sinus, without open-brain surgery. Described as the first FDA IDE trial of a permanently implanted BCI. Six patients with severe paralysis took part, at Mount Sinai, University at Buffalo and UPMC. No serious adverse events were reported. Participants used decoded motor intent for digital actions such as clicks and scrolling. A pivotal trial was under discussion with FDA as of 30 September 2024. [source: MassDevice 2024; Medical Design & Outsourcing 2024]
Neuralink (PRIME): FDA IDE in May 2023. First implant January 2024, second in August 2024. FDA Breakthrough Device designation for severe speech impairment in May 2025. The device is in the premarket phase, not authorised for marketing. [source: Medical Device Network 2025] Participant counts after May 2025 are [uncertain: not verified].
Therapist's use: Help the client separate research participation from treatment. Use the research team as the source for every technical and medical question.
Example language (illustrative): "This is a research study. The device isn't approved for general use, and the team's first job is to learn whether it's safe and workable. Let's think about what taking part would mean for you, including when the study ends."
Watch for: Therapeutic misconception (believing the study is designed to benefit them personally). Media-driven expectations. Pressure from others. Unasked questions about post-study support.

A4. Who delivers the treatment

Purpose / when [synthesis]: at the start of joint work, and whenever the client is unsure whom to ask, so that device, medical and research questions reach the right person.

BCI rehabilitation sits within rehabilitation medicine. Physicians prescribe it, and occupational therapists and physiotherapists usually deliver the training. [synthesis] These are registered professions. In the UK the regulator is the HCPC. In the US, practitioners hold state licensure, with NBCOT certification and AOTA as the professional body for occupational therapy, and APTA for physiotherapy. [uncertain: not verified] Implanted BCIs are placed by neurosurgical or neurointerventional teams within approved research protocols. [source: BrainGate; MassDevice 2024]
Therapist's use: Know who the client's named clinicians are and which of them handles device problems, medical problems and research questions.
Steps [synthesis]: (1) With consent, list the named clinicians and their roles (prescriber, delivering therapist, research team, GP). (2) Agree with the client which questions go to whom. (3) Record the agreed contacts and how you will share information with the team. (4) Revisit the list when the client moves between rehabilitation, research and community care.
Example language (illustrative): "Who on your team is the person to call if the device isn't working, and who if you feel unwell? Let's write both down."
Watch for: Unclear roles, or the client bringing device questions to you because the team feels hard to reach.

Part B: The psychotherapist's interventions

B1. Values-based decision support

Purpose: Help the client decide whether to pursue BCI rehabilitation or a trial, in line with their own values. Use before referral or enrolment, and when the decision is revisited. [synthesis]
Steps: (1) Elicit what the client most wants to be able to do (e.g. hold a cup, type, speak to family). (2) Map what the specific device is described to offer against that, using the team's information and the sources above. (3) List the costs: time, travel, effort, surgery (for implants), uncertainty, and how it ends. (4) Explore fears and hopes separately. (5) Check for pressure from family, clinicians or media. (6) Summarise and help the client form questions for the team. (7) Leave the decision with the client and the team.
Example language (illustrative): "If this worked as well as you hope, what would be different on an ordinary Tuesday? And if it helped only a little, would it still be worth it to you?"
Watch for: Deciding to please others. All-or-nothing hope. Avoiding talk about the downsides. Signs it is working: the client can state their own reasons and name at least one realistic outcome they would accept.

B2. Psychoeducation: cleared versus investigational, and realistic expectations

Purpose: Correct misunderstandings, especially between a cleared rehabilitation device and research implants seen in the news. [source: FDA 2021; Medical Device Network 2025; synthesis]
Steps: (1) Ask what the client has heard and where. (2) State the regulatory status as sources give it, with the date. (3) Explain the core idea in plain words: intention is detected and turned into movement or computer control. (4) Explain what the evidence base is, e.g. that IpsiHand's authorisation rested on an unblinded 40-person study. (5) Invite them to check details with the team.
Example language (illustrative): "What you saw on the news is a research implant. What your rehab doctor offered is a different, non-surgical device that the FDA authorised in 2021 for stroke rehab in adults. They're very different things."
Watch for: Confusion between the two kinds of device. Belief that a device will 'cure' paralysis. Disappointment once the gap becomes clear. Signs it is working: the client accurately explains back what the device is and is not.

B3. Supporting informed consent for trial participation

Purpose: Help the client engage fully with the research team's consent process. This does not replace it. [synthesis]
Steps: (1) Read the information sheet together if the client wishes. (2) Help them draft questions, e.g. about surgery and its risks, the time commitment and travel (BrainGate describes 13 months and a three-hour radius), who owns and accesses neural data, what happens at study end, whether the device stays or is removed, MRI implications, and what happens if the company stops trading. [source: BrainGate; IEEE Spectrum 2022; MIT Technology Review 2023] (3) Rehearse saying no or asking for time. (4) Check capacity concerns (e.g. after stroke or with progressive illness) and raise them with the team if present.
Example language (illustrative): "It's completely fine to ask, 'If the company runs out of money, what happens to me and the implant?' People in other implant studies have faced that."
Watch for: Therapeutic misconception. Fear of disappointing the researchers. Communication difficulties that make questions hard to ask; involve speech and language therapy or communication aids. Signs it is working: the client takes a written list of questions to the team.

B4. Neural data and privacy conversation

Purpose: Help clients understand that brain data are sensitive and that legal protection varies by place. [source: ABA article]
Steps: (1) Ask what data the device or app collects, and where it is stored. (2) Note the legal landscape as sources state it. Chile's constitution protects brain activity (amendment of 25 October 2021), and Chile's Supreme Court in August 2023 treated neural data as sensitive data. Colorado's HB 24-1058 treats neural data as sensitive data with opt-in consent (became law 17 April 2024). California added neural data to its privacy law effective 1 January 2025, with an opt-out model. [source: ABA article] (3) Help the client ask the team or company about data sharing, research reuse and deletion. (4) Do not give legal advice; refer to the study's privacy officer or a lawyer if needed.
Example language (illustrative): "Some places now treat brain data as specially protected. It's reasonable to ask the team who can see your recordings, whether they're shared, and what happens to them later."
Watch for: Paranoid or intrusive fears about mind-reading, which need gentle reality-testing and assessment if out of proportion. Also the opposite, an uncritical sharing of data. Signs it is working: the client has clear answers or knows whom to ask.

B5. Engagement, frustration and ambivalence about use

Purpose: Support sustained engagement in a demanding training routine. IpsiHand's study described use about five days a week for 12 weeks. [source: WashU 2021] Never advise changing how or how often the device is used; route that to the team. [synthesis]
Steps: (1) Ask how use is going in practice. (2) Explore ambivalence with a motivational-interviewing stance: reasons to continue, reasons it is hard. (3) Problem-solve barriers that are not about the device, such as routines, helpers and mood. (4) If the client wants to reduce or stop, help them take that to the prescriber. (5) Track small, client-defined gains.
Example language (illustrative): "Part of you is fed up with the sessions, and part of you doesn't want to waste the chance. Both make sense. Shall we take the 'fed up' part to your OT so they can hear it too?"
Watch for: Hidden non-use. Shame about "failing" the device. Fatigue that may need medical review. Signs it is working: honest reporting to the team and a sustainable routine.

B6. Agency and identity work

Purpose: Help the client integrate the device into their sense of self and of being the author of their actions. Address grief for the pre-injury self. [source: MIT Technology Review 2023 reporting Gilbert's interviews; synthesis]
Steps: (1) Ask how the client experiences actions made through the device: as "mine", as "the machine's", or as joint. (2) Normalise a range of experiences. One trial participant described the implant as a partner: "we became one". [source: MIT Technology Review 2023] (3) Use narrative work to place the device within the client's life story. (4) Explore changes in roles and self-image as function changes. (5) Prepare in advance for what loss of the device would mean.
Example language (illustrative): "When the cursor moves, does it feel like you moving it, the device, or both of you together? There's no right answer. I'm interested in what it's like for you."
Watch for: Estrangement ("it's not me doing it"). Over-dependence or fusion that makes any device problem catastrophic. Grief resurfacing. Signs it is working: a coherent, flexible story about self and device.

B7. Family and caregiver sessions

Purpose: Address caregivers' practical and emotional load, align expectations and reduce conflict over the decision. [synthesis]
Steps: (1) Hold a joint session with the client's consent. (2) Let each person state their hopes and worries. (3) Clarify the practical load: transport, set-up, supervising home use, travel to study sites. (4) Agree who contacts the team about what. (5) Offer caregivers their own support or referral.
Example language (illustrative): "It sounds like you're carrying a lot of the setting-up and driving. What would make this sustainable for you as well as for your partner?"
Watch for: A caregiver pushing harder than the client. Burnout. Role reversal and resentment. Signs it is working: a shared, realistic plan.

B8. Monitoring mood, fatigue and risk; passing on concerns; safety planning

Purpose: Detect post-stroke depression, adjustment problems and suicidality early, and pass physical concerns to the team. [synthesis]
Steps: (1) Screen mood and anxiety regularly with validated measures suited to aphasia or motor limitations where needed. (2) Ask about fatigue, discomfort and skin problems, and pass them to the treating team (these are FDA-listed adverse events for IpsiHand). [source: FDA 2021] (3) For implants, ask about new neurological symptoms or wound concerns and route them urgently to the research team. (4) Assess suicide risk with standard practice when hope collapses (e.g. failed trial, explantation). Make a safety plan that includes accessible crisis contacts and caregiver involvement.
Example language (illustrative): "You mentioned headaches since the procedure. That's one for the study team today, not next week. Would you like to call them from here?"
Watch for: Hopelessness after plateau. Minimising symptoms in order to stay in a study. Communication barriers that hide distress. Signs it is working: concerns reach the right clinician quickly.

B9. Collaboration and liaison with the treating or research team

Purpose: Integrate psychological care with rehabilitation or research care. [synthesis]
Steps: (1) Get written consent to share information. (2) Agree with the team what you will pass on (mood, risk, capacity concerns, distress about the device) and how. (3) Keep out of device decisions. (4) Ask the team for their information materials, so that your psychoeducation matches what they tell the client. (5) Document your communication.
Example language (illustrative): "With your permission, I'd like to let your rehab consultant know you've been low this month, so they can factor it in. I won't comment on the device itself."
Watch for: Splitting (the client tells you and the team different things). Gaps in role clarity. Signs it is working: a coordinated plan and the client feeling held by one team.

B10. Preparing for and processing endings: plateau, trial end, explantation, company failure

Purpose: Reduce the trauma of losing a device or its support. [source: MIT Technology Review 2023; IEEE Spectrum 2022]
Steps: (1) Early on, help the client ask what happens at study end, and what happens if the company fails. (2) Draw on documented cases as psychoeducation. NeuroVista ran out of money in 2013 and participants were advised to have implants removed; one participant described the loss as "They took away that part of me". Second Sight wound down in 2020 and Argus II recipients were left without repairs; one could not obtain implant information needed for an MRI. [source: MIT Technology Review 2023; IEEE Spectrum 2022] (3) Plan practical steps with the team: keep device documentation, MRI-relevant information and contact details for the clinicians. (4) After an ending, offer grief-focused and, if indicated, trauma-focused work. (5) Revisit identity (B6) and meaning.
Example language (illustrative): "This device became part of how you live. Losing it isn't 'just' losing equipment. It makes sense that it feels like losing a part of yourself."
Watch for: Traumatic stress, depression, anger at the company or team, and loss of trust in future care. Signs it is working: the client can grieve and still re-engage with rehabilitation and relationships.

B11. Hype, media and public attention

Purpose: Help clients handle publicity around high-profile BCI companies and requests to tell their own story. [synthesis]
Steps: (1) Explore what the client has seen and how it affects their hopes. (2) Separate press claims from the regulatory status (A3). (3) If the client is a trial participant, explore the pros and cons of media exposure and privacy, and check what the study's rules are.
Example language (illustrative): "Headlines move faster than the research. What did that story make you hope for, and what do you know about where things actually stand?"
Watch for: Comparison and envy, distress about public comments, privacy breaches. Signs it is working: the client makes deliberate choices about exposure.

Pointer

Biofeedback and neurofeedback delivered by psychotherapists are covered in their own Domain IX entries. Speech-language rehabilitation methods such as melodic intonation therapy are in Domain VIII (056).

5. Handling problems

Most guidance here is [synthesis]. The sources describe the devices and the documented harms of device loss; they do not describe psychotherapy processes.

Stuck: "nothing is changing" after weeks of BCI training. Validate the effort. Review client-defined small gains. Encourage the client to raise the plateau with the rehabilitation team, who decide on continuing or changing the plan. Screen for depression. [synthesis] Avoid implying that more effort will guarantee recovery.
- Example (illustrative): "You've worked hard and the change is smaller than you hoped. That's worth telling your OT plainly. And I want to check how your mood is holding up."
- Watch for: hopelessness and suicidal thinking (see B8).
Resistance or ambivalence about starting. Use a motivational stance. Explore fears (surgery, failure, losing benefits or identity as a disabled person, data). Respect a decision not to proceed. [synthesis]
- Example (illustrative): "Saying no to this is a legitimate choice too. What would you need to know to feel settled either way?"
Overwhelm from technology and information. Slow the pace. Break the device routine into steps the team has given. Use written summaries and involve a caregiver or the OT in practical set-up. [synthesis]
- Watch for: cognitive fatigue after stroke; adjust session length and use aphasia-friendly materials.
Non-adherence to device use. Explore it without judgement. Separate practical barriers from emotional ones. Help the client report honestly to the prescriber. Never advise changes to use. [synthesis]
- Example (illustrative): "If the headset's been sitting in the box, that's useful information, not a failure. How would it be to tell the team exactly that?"
Rupture: the client feels you are 'against' the device, or 'selling' it. Name the rupture, restate your role (support for their decision, not the device's champion or critic), and repair. [synthesis]
- Example (illustrative): "I may have sounded doubtful last week. My job isn't to push you towards or away from this. It's to help you think it through on your terms."
Therapeutic misconception in research participants. Gently re-state that the study's purpose is to test feasibility and safety, as BrainGate's own description says. Encourage the client to ask the investigators what benefit, if any, to expect. [source: BrainGate; synthesis]
Device failure or loss of company support. Treat it as a potential trauma and loss. Help secure practical information (documentation, MRI implications, contacts) through the team. Offer grief and trauma-focused work. Validate anger. [source: IEEE Spectrum 2022; MIT Technology Review 2023; synthesis]
- Watch for: loss of trust in all future care; reluctance to seek MRI or medical help.
Identity disturbance ("it's not really me moving", or fusion with the device). Use the identity work in B6. Explore feelings of control and authorship. Consider referral for neuropsychological assessment if changes in personality or cognition are suspected. [synthesis]
Fears about mind-reading or data misuse. Separate realistic privacy concerns from intrusive or paranoid fears. Give accurate information on data rights, as in B4. Assess and refer if fears reach delusional intensity. [source: ABA article; synthesis]
Family conflict over enrolment or explantation. Hold a joint session. Centre the client's autonomy and capacity. Involve the team's consent clinicians if capacity is in question. [synthesis]
Requests for DIY or unregulated neurotechnology (consumer EEG "rehab" apps, home-built stimulation). Do not give instructions. Express concern about safety and evidence, and direct the client to the treating team. [synthesis] The specific documented risks of DIY brain stimulation are [uncertain: not verified] in the sources used here.
Crisis. Follow standard suicide risk assessment and safety planning, with accessible formats for motor or speech impairment. Arrange urgent medical review for new neurological symptoms in implant recipients. [synthesis]

Sources

Not verified for this guide: Ang and colleagues' BCI stroke rehabilitation trials; EU, UK and other non-US regulatory status of all devices; Neuralink and Synchron status after the source dates above; text of Colorado HB 24-1058 and of the Chilean constitutional amendment (described here only as the ABA article reports them); professional regulators for occupational therapy and physiotherapy. [uncertain: not verified]

← Previous · IX-079Paired VNS for stroke rehabilitation (Vivistim)Next · IX-081 →Psychosomatic medicine (Uexküll) and the biopsychosocial model (Engel)